Corneal conditions that deny millions in low- and middle-income countries their right to sight are preventable, treatable, and often reversible. With your help, KeraLink International will eradicate corneal blindness everywhere.
Compassionate Capitalism: The Path Forward
Through collaboration, active engagement, and innovative funding approaches, KeraLink International (KLI) is developing a core business strategy: compassionate capitalism combines the efficiency and scalability of capital markets with philanthropy’s altruism and long-term vision. This is a new ecosystem designed to support sustainable interventions for corneal blindness, which currently denies 12.7 million people in low- and middle-income countries (LMICs) their right to sight and threatens the sight of many millions more. KLI’s visionary approach will bridge the chasm between profitability and social good. Our work in combating corneal blindness is just the beginning.
KLI Invest $2.5 Million in Bioengineered Implants
KLI established and provides seed funding to Pantheon Vision, an early-stage ophthalmic medical device company. KLI established Pantheon to pioneer bioengineered implants that will offer sustainable, affordable pathways to corneal health in LMICs. Such alternatives are critical because current treatments for corneal injury and blindness rely on human tissue transplants which are out of reach in LMICs due to the lack of necessary infrastructure, resources, and expertise for such complex procedures. KLI is committed to innovative solutions for the 12.7 million affected by corneal blindness globally – the majority of whom live in LMICs.
KeraLink International Participates in AAO 2023
KLI team members participated in AAO 2023, the annual meeting of the American Academy of Ophthalmology (AAO) which took place in San Francisco in November. AAO 2023 was one of the world’s largest ophthalmic meetings attended by 17,000 professionals from around the globe. The event was a terrific learning and networking opportunity for KLI team members, who were also on hand to honor our board member, Roberto Pineda II, M.D., as he won the prestigious 2023 José I. Barraquer Lecture and Award for his career contributions in the field of refractive surgery, and for his character and scientific dedication. Congratulations Dr. Pineda!!
Eradicating Corneal Blindness Globally
KeraLink International (KLI), a leader in corneal health, is pursuing three pivotal initiatives to eliminate corneal blindness in low- and middle-income countries (LMICs). These strategies encompass a novel corneal tissue substitute, a comprehensive global plan for the prevention and treatment of corneal ailments, and an international joint venture to address infectious keratitis, the primary cause of corneal blindness. KLI is focused on strategies that deliver preventive measures, early diagnosis, and novel treatments for the 12.7 million people impacted by corneal blindness globally, and particularly in LMICs.
{{event-card}}
KeraLink International (KLI) is a forward-thinking non-profit, 501(c)3 organization singularly focused on bringing clinicians, technology innovators, health care providers, philanthropists, and investors into a coordinated, collaborative effort to eradicate corneal blindness in low- and middle income countries.
